Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Publications

DNA prime and peptide boost immunization elicits robust neoantigen-specific CD8 + T cell responses and therapeutic protection in mouse tumor models.

Morgado-Cáceres P. et al, (2026), Oncoimmunology, 15

Nonclassical MHC-I Molecules: Emerging Therapeutic Targets in Next-Generation Immunotherapy.

He W. and McMichael AJ., (2026), MedComm, 7

Economic evaluation of alternative hepatitis C treatment options: a post hoc analysis of the VIETNARMS trial.

Turner HC. et al, (2026), EClinicalMedicine, 95

Safety and activity of RO7300490, a bispecific CD40 agonist targeted to fibroblast activation protein, in patients with advanced solid tumors: a single-arm, multicenter, first-in-human, phase 1 trial.

Melero I. et al, (2026), Nat Cancer

A first-in-human phase 1 clinical trial evaluating clinical activity and proof-of-mechanism of tobemstomig, a PD1-LAG3 bispecific antibody, in patients with CPI-experienced melanoma.

Garralda E. et al, (2026), Clinical cancer research : an official journal of the American Association for Cancer Research

Cibisatamab and FAP-4-1BBL in microsatellite-stable colorectal cancer: a phase 1b trial.

Melero I. et al, (2026), Nature medicine

Upstream ORFs control TNFR1 abundance and tissue tolerance to TNF.

Ma B. et al, (2026), Science immunology, 11

Using peptide-exchange systems to interrogate peptide-specific KIR binding to HLA Class I

Murali TM. et al, (2026)

Intratumoral heterogeneity and immunotherapy resistance: clinical implications.

Keenan BP. et al, (2026), Annals of oncology : official journal of the European Society for Medical Oncology, 37, 314 - 328

Safety, Feasibility, and Pharmacodynamic Activity of Intratumoral Injections of the Agonist Anti-CD137 (4-1BB) mAb Urelumab in Combination with Nivolumab.

Sanmamed MF. et al, (2026), Clinical cancer research : an official journal of the American Association for Cancer Research, 32, 1036 - 1045

Chromosomal instability shapes the tumor microenvironment of esophageal adenocarcinoma via a cGAS-chemokine-myeloid axis.

Beernaert B. et al, (2026), Science advances, 12

Fine-tuning BACH2 dosage balances stemness and effector function to enhance antitumor T cell therapy.

Conti AG. et al, (2026), Nature immunology, 27, 436 - 451

Evolutionary dynamics of epitopes of limited variability on the head of influenza H1 haemagglutinin.

Lourenço J. et al, (2026), Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases, 140

Risk Factors of Metabolic Dysfunction-associated Steatotic Liver Disease in a Cohort of Patients With Chronic Hepatitis B.

Kalafateli M. et al, (2026), Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 24, 701 - 712.e8

Tumor-targeted 4-1BB costimulation enhances immune activation and clinical activity of a CEA-directed T-cell engager in microsatellite-stable colorectal cancer

Boehnke A. et al, (2026)

Load More

1
2
3
4
5
6
7
...
»